Jul 13, 2017
In the second of her articles on value assessment, Leela Barham discusses the emergence of multiple frameworks in the US and considers their impact.
Jul 11, 2017
Maiko Midena discusses the key fundamentals to success when it comes to forecasting with large multinational pharmaceutical organizations.
Jul 10, 2017
Just as internal company compliance regulation needs to change, so too does compliance education, writes Dr. Nick Broughton.
Jul 07, 2017
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Three messages that resonated from this year’s annual meeting of the Drug Information Association.
Jul 07, 2017
Pharmaceutical Executive
As we step further into the waters of value-based contracting arrangements, lessons learned must be shared—including the role of the patient in the equation.
Jul 06, 2017
The FDA ruling that exempts biosimilar makers from waiting an extra six months after approval to distribute a new product should help overcome delays in future biosimilar sales, writes Jill Wechsler.
Jun 26, 2017
Intellectual property analysis of one recently approved drug shows how Valeant might have missed out on at least one vital acquisition opportunity. Duncan Clark reports.
Jun 26, 2017
Pharmaceutical Executive
Outlining the new leadership and C-level roles of tomorrow needed to take on the disruption event on pharma's horizon.
Jun 19, 2017
Pharmaceutical Executive
Last month’s EFPIA and EU Health Council annual conferences highlighted the growing divisions—and resentments—between industry and governments on drug pricing. Reflector reports.
Jun 16, 2017
Congressional measures lack the support to move forward, writes Jill Wechsler.
lorem ipsum